AstraZeneca decided to stop paying clinicians to attend scientific meetings overseas amid regulatory scrutiny of
drugmakers' financial relationship with the medical community. AstraZeneca will focus instead on "local
educational opportunities," CEO David Brennan said. The drug industry reportedly paid the government $15 billion in fines during the past five years for violation of federal law.